From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Elamipretide structure.svg
Clinical data
Other namesH-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
CAS Number
PubChem CID
Chemical and physical data
Molar mass639.802 g·mol−1

Elamipretide (also known as SS-31, , MTP-131 and Bendavia)[1][2] is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.[3]

Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.[4][5]

As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication.[2]


  1. ^ "Recommended INN List 75" (PDF). WHO Drug Information. 30 (1): 111. 2016.
  2. ^ a b "Elamipretide". AdisInsight. Retrieved 29 November 2017.
  3. ^ Kloner, RA; Shi, J; Dai, W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling". Annals of Translational Medicine. 3 (2): 20. doi:10.3978/j.issn.2305-5839.2015.01.13. PMC 4322169. PMID 25738140.
  4. ^ Valigra, Lori (April 9, 2012). "Stealth Peptides sees positive results from Bendavia". Boston Business Journal.
  5. ^ Dolgin, Elie (11 February 2016). "New drugs offer hope for mitochondrial disease". STAT.